Big Bank Rating | Damo: Raising the target price of Chinese medicines to HK$5.4, attracting valuation
China Traditional Chinese Medicine (00570.HK) Investment Value Analysis Report: Leading Chinese Medicine Formulation Granules Continue to Deepen the Layout of the Whole Industry Chain
No. 1 Shanghai: Maintaining a “buy” rating target price of HK$4.3 for Chinese traditional Chinese medicine (00570)
Chinese Traditional Chinese Medicine (0570.HK): Building a Traditional Chinese Medicine Group with a Whole Industry Chain to Collect Formulated Particles Brings Disturbance
Chinese Traditional Chinese Medicine (00570.HK): 1H23 performance is in line with expectations, formula granules achieve restorative growth
Big Bank Ratings丨Morgan Stanley: Lowering the Target Price of Chinese Medicine to HK$5.2 Rating to “Increase Holding”
Chinese Traditional Chinese Medicine (00570.HK): The formula pellet business is affected by the change in national standards in the short term and is expected to achieve a healthy recovery in 2023
League of Nations Securities: Maintaining the target price of the “buy” rating for Chinese Traditional Chinese Medicine (00570) at HK$5.48
Big Bank Ratings | Jefferies: Raise the target price of Chinese Traditional Chinese Medicine (0570.HK) to HK$5.5 to buy
League of Nations Securities: The increase in national standards is expected to accelerate the growth of formula particles and give the industry a “better than the market” rating
China Traditional Chinese Medicine (00570.HK) Hong Kong Stock Company Information Update Report: The month-on-month improvement on the operating side in the second half of the year is optimistic that growth will resume relatively quickly in 2023
Chinese Traditional Chinese Medicine (0570.HK): Prescribing pellets to lay out the entire traditional Chinese medicine industry chain
Chinese Traditional Chinese Medicine (00570.HK): Performance is in line with expectations, the formula granule business is expected to gradually recover
Chinese Traditional Chinese Medicine (0570.HK): The end of the pilot formula, volume and price have risen sharply, and the collaborative development of the entire upstream and downstream industries of traditional Chinese medicine highlights leading advanta
China Traditional Chinese Medicine (00570.HK) Hong Kong Stock Company's First Coverage Report: Leading Advantages of Traditional Chinese Medicine Formulation Granules Clearly Prioritize Industry Expansion
Chinese Traditional Chinese Medicine (0570.HK): Chinese medicine formula granules will lead steady growth in performance
Chinese Traditional Chinese Medicine (00570.HK): Performance exceeded expectations, further increased the share of revenue from formula granules
China Traditional Chinese Medicine (0570.HK): Revenue from main business grew steadily
China traditional Chinese Medicine (00570.HK): 1H21 performance is in line with expected steady sales growth in all sectors
China Traditional Chinese Medicine (0570.HK): Controlling shareholder suspends privatization plan and suggests wait-and-see in the short term
No Data